(NSCLC) is a heterogeneous group of carcinomas with a similar cellular and molecular
origin but different biologic behaviors and prognoses. Accurate staging is essential for …

PET/CT with the glucose analog 18F-FDG has several potential applications for monitoring
tumor response to therapy in patients with non–small cell lung cancer (NSCLC). A …

This study aimed to evaluate the prognostic value of 2-[18F] fluoro-2-deoxy-D-glucose (18F-
FDG) uptake determined by positron emission tomography (PET) in patients with non-small …

Background The aim of this study is to investigate the underlying biologic mechanisms of 2-
[18 F]-fluoro-2-deoxy-d-glucose (18 F-FDG) uptake on positron emission tomography (PET) …

PURPOSE: The amount of radio-labeled 18F-fluoro-2-deoxy-glucose (FDG) uptake, a
measurement of the increased glucose metabolism of non–small-cell lung cancer (NSCLC) …

18F-FDG PET can help in predicting therapeutic response and outcome in patients with
metastatic pulmonary tumors. However, no satisfactory biologic explanation exists for this …

Introduction: The prognostic value of quantitative 18F-fluoro-2-deoxy-d-glucose (FDG)
uptake on positron emission tomography (PET) is controversial in unselected patients with …

Abstract 18 F-fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic
information that characterizes lesions that are indeterminate by CT. FDG PET imaging is …

The aim of this study was to determine whether quantitative information obtained from [18 F]
fluorodeoxyglucose positron emission tomography (18 F-FDG PET) has a prognostic …

[18 F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is a promising
imaging procedure for detecting primary and metastatic cancer in the lungs. We have …